Oculis Holding AG (NASDAQ:OCS) Shares Sold by Pivotal bioVenture Partners Investment Advisor LLC

Pivotal bioVenture Partners Investment Advisor LLC lessened its stake in Oculis Holding AG (NASDAQ:OCS) by 14.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,888,788 shares of the company’s stock after selling 329,966 shares during the quarter. Oculis comprises approximately 5.4% of Pivotal bioVenture Partners Investment Advisor LLC’s investment portfolio, making the stock its 3rd biggest holding. Pivotal bioVenture Partners Investment Advisor LLC owned approximately 5.19% of Oculis worth $21,211,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of OCS. abrdn plc acquired a new position in shares of Oculis during the fourth quarter valued at $15,980,000. Searle & CO. bought a new position in shares of Oculis in the 4th quarter valued at about $112,000. Compagnie Lombard Odier SCmA grew its position in shares of Oculis by 47.3% during the 4th quarter. Compagnie Lombard Odier SCmA now owns 95,750 shares of the company’s stock worth $1,053,000 after buying an additional 30,750 shares during the period. Finally, Wolverine Asset Management LLC bought a new stake in shares of Oculis during the third quarter worth approximately $77,000. 22.30% of the stock is owned by institutional investors.

Oculis Stock Down 0.8 %

NASDAQ OCS traded down $0.10 during trading on Friday, hitting $11.85. The stock had a trading volume of 1,465 shares, compared to its average volume of 11,879. The company has a market capitalization of $479.93 million, a PE ratio of -6.66 and a beta of 0.30. The company’s 50-day moving average price is $11.95 and its two-hundred day moving average price is $11.70. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.71 and a current ratio of 4.71. Oculis Holding AG has a 12 month low of $9.05 and a 12 month high of $14.50.

Oculis (NASDAQ:OCS) last released its earnings results on Wednesday, May 8th. The company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.41) by ($0.03). Oculis had a negative net margin of 6,712.02% and a negative return on equity of 52.72%. The firm had revenue of $0.22 million during the quarter, compared to the consensus estimate of $0.28 million. As a group, sell-side analysts forecast that Oculis Holding AG will post -1.84 EPS for the current year.

Wall Street Analysts Forecast Growth

OCS has been the topic of several analyst reports. Robert W. Baird cut their target price on Oculis from $64.00 to $35.00 and set an “outperform” rating on the stock in a research note on Tuesday, March 19th. HC Wainwright reaffirmed a “buy” rating and issued a $28.00 target price on shares of Oculis in a research note on Thursday, May 30th. Wedbush reissued an “outperform” rating and set a $29.00 price target on shares of Oculis in a research report on Wednesday, March 6th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $30.00 price objective on shares of Oculis in a research note on Tuesday, March 19th. Eight analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $30.17.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.